<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013136</article-id><article-id pub-id-type="pmc">PMC11861550</article-id><article-id pub-id-type="doi">10.3389/fimmu.2025.1512279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>CD21<sup>low</sup> B cells reveal a unique glycosylation pattern with hypersialylation and hyperfucosylation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Felixberger</surname><given-names>Peter Tobias</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2868831"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Andrieux</surname><given-names>Geoffroy</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/843449"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Maul-Pavicic</surname><given-names>Andrea</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2924872"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Goldacker</surname><given-names>Sigune</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/164143"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Harder</surname><given-names>Ina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Gutenberger</surname><given-names>Sylvia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Landry</surname><given-names>Jonathan J. M.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Benes</surname><given-names>Vladimir</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/25207"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Jakob</surname><given-names>Till Fabian</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/572522"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Boerries</surname><given-names>Melanie</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/998183"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Nitschke</surname><given-names>Lars</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/38736"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Voll</surname><given-names>Reinhard Edmund</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/274423"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Warnatz</surname><given-names>Klaus</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/19333"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Keller</surname><given-names>Baerbel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/939610"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Genomics Core Facility, European Molecular Biology Laboratory</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Oto-Rhino-Laryngology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg</institution>, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Division of Genetics, Department of Biology, University of Erlangen</institution>, <addr-line>Erlangen</addr-line>, <country>Germany</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Ale&#x00161; Janda, Ulm University Medical Center, Germany</p></fn><fn fn-type="edited-by"><p>Reviewed by: Catarina Greg&#x000f3;rio Martins, New University of Lisbon, Portugal</p><p>Changsong Wang, The 989th Hospital of the PLA Joint Logistic Support Force, China</p></fn><corresp id="fn001">*Correspondence: Klaus Warnatz, <email xlink:href="mailto:klaus.warnatz@uniklinik-freiburg.de">klaus.warnatz@uniklinik-freiburg.de</email>
</corresp><fn fn-type="equal" id="fn003"><p>&#x02020;These authors have contributed equally to this work and share last authorship</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1512279</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Felixberger, Andrieux, Maul-Pavicic, Goldacker, Harder, Gutenberger, Landry, Benes, Jakob, Boerries, Nitschke, Voll, Warnatz and Keller</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Felixberger, Andrieux, Maul-Pavicic, Goldacker, Harder, Gutenberger, Landry, Benes, Jakob, Boerries, Nitschke, Voll, Warnatz and Keller</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>The posttranslational modification of cellular macromolecules by glycosylation is considered to contribute to disease pathogenesis in autoimmune and inflammatory conditions. In a subgroup of patients with common variable immunodeficiency (CVID), the occurrence of such complications is associated with an expansion of na&#x000ef;ve-like CD21<sup>low</sup> B cells during a chronic type 1 immune activation. The glycosylation pattern of B cells in CVID patients has not been addressed to date.</p></sec><sec><title>Objective</title><p>The objective of this study was to examine the surface glycome of B cells in patients with CVID and associated immune dysregulation.</p></sec><sec><title>Methods</title><p>We performed surface lectin staining on B cells from peripheral blood and tonsils, both <italic>ex vivo</italic> and after <italic>in vitro</italic> stimulation. Additionally, we examined the expression of glycosylation-related genes by RNAseq in na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic>, as well as in na&#x000ef;ve CD21<sup>pos</sup> B cells from healthy controls after <italic>in vitro</italic> stimulation.</p></sec><sec><title>Results</title><p>Unlike CD21<sup>pos</sup> B cells, na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients and CD21<sup>low</sup> B cells from healthy controls exhibited a unique glycosylation pattern with high levels of &#x003b1;2,6 sialic acids and fucose. This hypersialylation and hyperfucosylation were particularly induced by activation with anti-IgM and interferon-&#x003b3; (IFN-&#x003b3;). Transcriptome analysis suggested that na&#x000ef;ve-like CD21<sup>low</sup> B cells possess a comprehensively reorganised glycosylation machinery, with anti-IgM/IFN-&#x003b3; having the potential to initiate these changes <italic>in vitro</italic>.</p></sec><sec><title>Conclusion</title><p>CD21<sup>low</sup> B cells are hypersialylated and hyperfucosylated. This may implicate altered lectin-ligand interactions on the cell surface potentially affecting the CD21<sup>low</sup> B-cell function. These glycome changes appear to be driven by the prominent type I immune response in complicated CVID patients. A better understanding of how altered glycosylation influences immune cell function could lead to new therapeutic strategies.</p></sec></abstract><kwd-group><kwd>CD21low B cells</kwd><kwd>CVID</kwd><kwd>glycome</kwd><kwd>glycosylation</kwd><kwd>hypersialylation</kwd><kwd>hyperfucosylation</kwd><kwd>anti-IgM/IFN&#x003b3;</kwd><kwd>T-bet</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the German Research Foundation TRR130 TP07 to KW. KW also receives support from the German Federal Ministry of Education and Research (BMBF) through a grant to the German Genetic Multi-Organ Auto-Immunity Network (GAIN), grant code 01GM2206A. BK receives support from the Deutsche Forschungsgemeinschaft (DFG; Project ID 545533246). Additionally, this work was supported by the DFG within the CRC1160 (Project ID 256073931-Z02 to MB), CRC/TRR167 (Project ID 259373024-Z01, MB), CRC1453 (Project ID 431984000-S1, MB), CRC1479 (Project ID: 441891347-S1 to MB), TRR 359 (Project ID 491676693-Z01, MB), and FOR 5476 UcarE (Project ID 493802833-P7, MB). Further support was provided by the German Federal Ministry of Education and Research (BMBF) within the Medical Informatics Funding Scheme PM4Onco-FKZ 01ZZ2322A (MB) and EkoEstMed-FKZ 01ZZ2015 (GA). We acknowledge the support of the Open Access Publication Fund of the University of Freiburg.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="0"/><equation-count count="0"/><ref-count count="78"/><page-count count="14"/><word-count count="5865"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Primary Immunodeficiencies</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Common variable immunodeficiency (CVID) is the most prevalent human antibody deficiency syndrome. In addition to recurrent infections, up to 60% of CVID patients present with noninfectious complications, such as autoimmunity, lymphoproliferation, and organ inflammation (CVIDc) (<xref rid="B1" ref-type="bibr">1</xref>). B-cell differentiation in these patients is typically characterised by a reduction in class-switched memory (cs mem) B cells and plasma cells. A subgroup of these patients further presents with an accumulation of na&#x000ef;ve-like CD21<sup>low</sup> B cells, classified as CVID smB-21lo patients according to the EUROclass classification (<xref rid="B2" ref-type="bibr">2</xref>). CD21<sup>low</sup> B cells constitute a B-cell subset that is characterised by the common and uniquely high expression of the transcription factor T-box expressed in T cells (T-bet) (<xref rid="B3" ref-type="bibr">3</xref>), most prominently induced by interferon-&#x003b3; (IFN-&#x003b3;) and B-cell receptor (BCR) costimulation, the integrin CD11c, and a strongly divergent gene expression profile compared to conventional B-cell subsets (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). CD21<sup>low</sup> B cells are infrequent in healthy individuals and expand not only in the peripheral blood of CVIDc patients but also in distinct autoimmune and infectious disease conditions such as systemic lupus erythematosus (SLE) (<xref rid="B6" ref-type="bibr">6</xref>), rheumatoid arthritis (RA) (<xref rid="B7" ref-type="bibr">7</xref>), Sj&#x000f6;gren&#x02019;s syndrome (<xref rid="B8" ref-type="bibr">8</xref>), chronic HIV infection (<xref rid="B9" ref-type="bibr">9</xref>), malaria (<xref rid="B10" ref-type="bibr">10</xref>) and others (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). As the differentially expressed genes (DEGs) of CD21<sup>low</sup> B cells contained some enzymes involved in glycosylation, and, in addition, an altered glycome has been&#x000a0;suggested to contribute to disease pathogenesis in autoimmune disorders (<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>), we set out to explore the glycome of na&#x000ef;ve-like CD21<sup>low</sup> B cells of CVIDc patients in more detail. Indeed, our investigations uncovered, for the first time, comprehensive aberrations in the glycome of CD21<sup>low</sup> B cells in CVID smB-21lo patients and healthy individuals, which might, in part, be direct subjects to the transcriptional regulation of T-bet.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Patient cohort and ethics statement</title><p>The current study included blood from 23 patients (14 women, nine mem; age: median 50 years &#x000b1; 13 years) who fulfilled the diagnostic criteria for CVID (<ext-link xlink:href="http://www.ESID.org" ext-link-type="uri">www.ESID.org</ext-link>). All patients were classified as CVID smB-21lo according to the EUROclass classification (<xref rid="B2" ref-type="bibr">2</xref>) and suffered from additional immune dysregulation, as listed in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S1</bold>
</xref>. Control blood and tonsils were obtained from healthy donors (HD) without known immunodeficiency. All experiments were performed with ethical approval from local authorities (251/13 and 254/19) in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients, healthy individuals, or their parents. Tonsillectomies were performed for medical reasons.</p></sec><sec id="s2_2"><label>2.2</label><title>Antibodies and lectins used in this study</title><p>The following antibodies and lectins were used: CD3 PE/Cy7 (UCHT1), CD4 BV421 (RPA-T4), sialyl-Lewis X (SLe<sup>X</sup>) AF488 (FH6), CD19 APC/Cy7 (HIB19), CD21 PE/Cy7 (Bu32), CD27 BV421 (M-T271), CD38 PerCP/Cy5.5 (HIT2), IgD BV785 (IA6-2), IgM BV605 (MHM-88) were obtained from BioLegend (San Diego, CA, USA). CD3 BUV395 (UCHT1), CD27 BV605 (L128), IgG AF700 (G18-145), and streptavidin APC (70312) for the detection of biotinylated lectins were obtained from BD Biosciences (Franklin Lakes, NJ, USA). CD19 PE/Cy7 (J3-119), and CD21 PE (BL13) were obtained from Beckman Coulter (Brea, CA, USA). IgD PE (polyclonal), IgD FITC (polyclonal), and IgM Cy5 (polyclonal) were obtained from SouthernBiotech (Birmingham, AL, USA). <italic>Sambucus nigra</italic> agglutinin (SNA) FITC (ZE0328), <italic>Lens culinaris</italic> agglutinin (LCA) FITC (ZD0104), <italic>Aleuria aurantia</italic> lectin (AAL) FITC (ZE0628), and <italic>Erythrina cristagalli</italic> lectin (ECL) biotinylated (ZB042) were obtained from Vector Laboratories (Newark, CA, USA). Lectin-binding properties and symbol nomenclature for graphical representations of glycans (<xref rid="B19" ref-type="bibr">19</xref>) are shown in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S1</bold>
</xref>. All glycans were created using the web software DrawGlycan (<xref rid="B20" ref-type="bibr">20</xref>).</p></sec><sec id="s2_3"><label>2.3</label><title>Cell isolation</title><p>PBMCs were isolated from EDTA blood by Ficoll density gradient centrifugation following standard protocols. For <italic>in vitro</italic> cultures, na&#x000ef;ve B cells were isolated using the na&#x000ef;ve B-Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Rhineland, Germany) following the manufacturer&#x02019;s instructions. To determine the purity of na&#x000ef;ve B cells, cells were stained with IgD FITC, CD21 PE, CD38 PerCpCy5.5, CD3 PC7, IgM Cy5, CD19 APC-Cy7, CD4 BV421, and CD27 BV605. Purity was above 93%. Tonsil cells were obtained by mechanical dissociation. After isolation, cells were resuspended in IMDM (Life Technologies, Carlsbad, CA, USA) with 10% foetal calf serum (FCS; Biochrom, Cambridge, Cambridgeshire, United Kingdom).</p></sec><sec id="s2_4"><label>2.4</label><title>Flow cytometric staining</title><p>Harvested cells were washed two to three times in phosphate-buffered saline (PBS; Lonza Basel, Switzerland) 1% bovine serum albumin (BSA; Sigma-Aldrich St. Louis and Burlington, MA, USA). Cell surface lectin staining was performed separately for each lectin (SNA FITC, LCA FITC, AAL FITC ECL biotinylated) for 15 min on ice. Cells were washed with PBS containing 1% BSA. For ECL, cells were subsequently stained with streptavidin APC for 15 min on ice. Antibody staining was then performed for 15 min at 4&#x000b0;C. PBMCs and tonsil cells were stained with IgD PE, CD38 PerCpCy5.5, CD21 PC7, CD19 APC-Cy7, and CD27 BV421 to determine the respective B-cell subsets. For flow cytometric analysis of na&#x000ef;ve activated B cells, cells were stained with IgD PE and CD19 PC7, and DAPI was added to exclude dead cells prior to data acquisition. Data were acquired using an LSRFortessa (BD Biosciences) and analysed using FlowJo software (Treestar, Ashland, OR, USA).</p></sec><sec id="s2_5"><label>2.5</label><title>
<italic>In vitro</italic> culture assay</title><p>For B-cell activation, 50,000 isolated na&#x000ef;ve B cells were stimulated with anti-IgM (5 &#x000b5;g/ml; SouthernBiotech, Birmingham, AL, USA), IFN-&#x003b3; (50 ng/ml; BioLegend), CpG oligodeoxynucleotides (2.5 &#x000b5;g/ml, InvivoGen, San Diego, CA, USA), or cultivated without additional stimulus in IMDM supplemented with <sc>l</sc>-glutamine, <sc>l</sc>-glutathione, insulin, apo-transferrin (all Sigma-Aldrich), nonessential amino acids (Gibco, Waltham, MA, USA), and 10% FCS for 48 h as described before (<xref rid="B5" ref-type="bibr">5</xref>). Cells were harvested and processed for flow cytometry or RNAseq.</p></sec><sec id="s2_6"><label>2.6</label><title>RNAseq</title><p>After stimulation, B cells were resuspended in RLT buffer (Qiagen, Shanghai, China) and frozen at &#x02212; 80&#x000b0;C. RNA was isolated using the RNAeasy Micro Kit (Qiagen) according to the manufacturer&#x02019;s instructions. Samples were processed and sequenced as described previously (<xref rid="B5" ref-type="bibr">5</xref>). Alignments and gene count tables were obtained for each sample using STAR (version 2.4.2a) on the GRCh38 genome and annotation (GRCh38.p7). Differential gene expression was analysed using the limma R package. An adjusted <italic>p</italic>-value (Benjamini and Hochberg) &#x0003c; 0.05 was considered significant. The original raw files are available in the Gene Expression Omnibus data repository of the National Center for Biotechnology Information (<xref rid="B21" ref-type="bibr">21</xref>) under the accession number GSE181739 for anti-IgM/IFN-&#x003b3; <italic>in vitro</italic>-stimulated B cells or GSE148163 for na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic>.</p></sec><sec id="s2_7"><label>2.7</label><title>Statistics</title><p>Statistical analyses were performed using GraphPad Prism 10 (GraphPad Software Inc., San Diego, CA, USA). Normal distribution was determined using D&#x02019;Agostino and Pearson or Shapiro&#x02013;Wilk test. Data were analysed using repeated measures one-way ANOVA with Tukey&#x02019;s multiple comparisons test for normally distributed results and Friedman&#x02019;s test with Dunn&#x02019;s multiple comparisons test for nonnormally distributed results, as indicated. <italic>p</italic>-values of less than 0.05 were considered significant: <sup>*</sup>
<italic>p</italic> &#x0003c; 0.05; <sup>**</sup>
<italic>p</italic> &#x0003c; 0.01; <sup>***</sup>
<italic>p</italic> &#x0003c; 0.001; and <sup>****</sup>
<italic>p</italic> &#x0003c; 0.0001. Error bars in all figures define the means &#x000b1; standard deviation (SD).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>Cell surface glycome of CD21<sup>low</sup> B cells</title><p>To address the question of whether the glycome of CVID patients&#x02019; B cells, and especially of CD21<sup>low</sup> B cells, is altered, we performed lectin staining of B cells from CVID smB-21lo patients and compared these to their CD21<sup>pos</sup> B-cell counterparts in patients and HD. Glycan binding properties for SNA (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>), ECL (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">24</xref>), AAL (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B25" ref-type="bibr">25</xref>), LCA (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>), and anti-SLe<sup>X</sup> are shown in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S1</bold>
</xref>. The gating strategy for na&#x000ef;ve, IgM memory (IgM mem), cs mem, and CD21<sup>low</sup> B cells is depicted in <xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1A</bold>
</xref>. Due to the low memory cell numbers in CVID patients, we restricted the analysis of CD21<sup>low</sup> B cells to the na&#x000ef;ve B-cell compartment.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Sialylation on CVID patients&#x02019; B cells. <bold>(A)</bold> Na&#x000ef;ve, IgM memory (IgM mem), and class-switched memory B cells (cs mem) were defined based on IgD and CD27 expression after gating on CD19<sup>pos</sup>CD21<sup>pos-low</sup> B cells. Subpopulations were further differentiated into CD21<sup>pos</sup> and CD21<sup>low</sup> subsets. <bold>(B)</bold> Representative histogram for na&#x000ef;ve B cells from one HD, na&#x000ef;ve CD21<sup>pos</sup>, and na&#x000ef;ve-like CD21<sup>low</sup> B cells from a CVID patient, with corresponding statistical analysis of mean fluorescence intensities (MFI) after SNA staining (<italic>n</italic> = 19). <bold>(C)</bold> Representative histogram for ECL staining as described in <bold>(A)</bold> (<italic>n</italic> = 16). Lectin-binding epitopes are illustrated. <italic>p</italic>-values as determined by one-way ANOVA with Tukey&#x02019;s multiple comparisons test <bold>(B, C)</bold>. **p &#x0003c; 0.01; ***p &#x0003c; 0.001; and ****p &#x0003c; 0.0001.</p></caption><graphic xlink:href="fimmu-16-1512279-g001" position="float"/></fig><p>Lectin staining with &#x003b1;2,6 sialic acid-binding SNA (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>) revealed significantly increased levels of SNA ligands on the surface of na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from patients or HD. In contrast, patients&#x02019; na&#x000ef;ve CD21<sup>pos</sup> B cells were comparable to those from HD (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1B</bold>
</xref>). ECL binds terminal &#x003b2;1,4-linked galactose (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">24</xref>), representing an asialylated form of SNA ligands (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S1</bold>
</xref>). In line with increased SNA binding, ECL staining demonstrated a reduction of ligands on the surface of na&#x000ef;ve-like CD21<sup>low</sup> B cells from patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from patients and HD. Na&#x000ef;ve CD21<sup>pos</sup> B cells from patients and HD exposed ECL ligands to a similar extent (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1C</bold>
</xref>). Overall, these data reveal &#x003b1;2,6 hypersialylation of na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients.</p><p>AAL binds to &#x003b1;1,3-, &#x003b1;1,4-, and &#x003b1;1,6-fucosylated glycans (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Lectin staining revealed an increased expression of AAL ligands on the surface of na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from patients or HD (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2A</bold>
</xref>). Similarly, lectin staining with LCA, which binds selectively to N-glycans with &#x003b1;1,6-linked core fucose (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>), was increased on na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from patients and HD (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2B</bold>
</xref>). The mean fluorescence intensity (MFI) of both lectins was similar in na&#x000ef;ve CD21<sup>pos</sup> B cells from patients and HD. Given the prominent role of SLe<sup>X</sup>, an &#x003b1;1,3 fucose-containing selectin ligand, on leukocyte trafficking, we analysed its expression on na&#x000ef;ve B cells (<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). Consistent with increased AAL staining, anti-SLe<sup>X</sup> staining demonstrated elevated levels of SLe<sup>X</sup> on patients&#x02019; na&#x000ef;ve-like CD21<sup>low</sup> B cells compared to patients&#x02019; and HD&#x02019;s na&#x000ef;ve CD21<sup>pos</sup> B cells. Na&#x000ef;ve CD21<sup>pos</sup> B cells from patients tended to have increased SLe<sup>X</sup> expression compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from HD, although this did not reach statistical significance (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2C</bold>
</xref>). The fucosylation pattern of na&#x000ef;ve-like CD21<sup>low</sup> B cells supports increased &#x003b1;1,3-, &#x003b1;1,4-, and/or &#x003b1;1,6-linked fucose, increased core fucosylation of N-glycans, and increased SLe<sup>X</sup> epitopes relative to na&#x000ef;ve CD21<sup>pos</sup> B cells.</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Fucosylation on CVID patients&#x02019; B cells. <bold>(A)</bold> Representative histogram for AAL in na&#x000ef;ve CD21<sup>pos</sup> B cells from a HD and na&#x000ef;ve CD21<sup>pos</sup> and na&#x000ef;ve-like CD21<sup>low</sup> B cells from a CVID patient, with corresponding statistical analysis (<italic>n</italic> = 20). <bold>(B, C)</bold> LCA (<italic>n</italic> = 18) and anti-SLe<sup>X</sup> (<italic>n</italic> = 5) staining as described in <bold>(A)</bold>. Lectin/antibody-binding epitopes are illustrated. <italic>p</italic>-values as determined by one-way ANOVA with Tukey&#x02019;s multiple comparisons test <bold>(A, B)</bold> and Friedman&#x02019;s test with Dunn&#x02019;s multiple comparisons test <bold>(B)</bold>. *p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.001; and ****p &#x0003c; 0.0001.</p></caption><graphic xlink:href="fimmu-16-1512279-g002" position="float"/></fig><p>We further tested whether external factors might influence the glycosylation of B cells in our patients. We did not observe any correlation between age or sex and the glycosylation of CD21<sup>low</sup> or CD21<sup>pos</sup> B cells in our patients (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figures S2A, B</bold>
</xref>). Genetic alterations (chromosome 22 aberrations, <italic>CTLA4</italic> or <italic>KMT2D</italic> mutation) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S2C</bold>
</xref>) and therapeutic treatments, such as low-dose steroids or sirolimus (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S2D</bold>
</xref>), did not affect the surface glycosylation pattern of na&#x000ef;ve-like CD21<sup>low</sup> and CD21<sup>pos</sup> B cells. Lastly, we tested if noninfectious complications, which are common in CVID patients with an accumulation of the CD21<sup>low</sup> B-cell subset, were associated with glycome aberrations. We separated patients according to the presence of splenomegaly, granuloma formation, granulomatous lymphocytic interstitial lung disease (GLILD)/interstitial lung disease (ILD), lymphoproliferation (LP), autoimmune organ manifestation (AIO), autoimmune cytopenia (AIC), enteropathy, and hepatopathy. None of these clinical manifestations was specifically associated with significant changes in the surface glycome (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S3</bold>
</xref>). Overall, these results indicate: (A) that the glycosylation pattern of B cells in CVID is <italic>per se</italic> not strongly influenced by these factors and (B) that the alterations are characteristic for the na&#x000ef;ve-like CD21<sup>low</sup> B-cell subset, in contrast to the CD21<sup>pos</sup> B-cell compartment.</p></sec><sec id="s3_2"><label>3.2</label><title>Cell surface glycome of B-cell subsets from healthy controls</title><p>Next, to determine whether the altered glycome observed in CD21<sup>low</sup> B cells from CVID patients is unique to these cells, we compared the glycome of different B-cell subsets derived from peripheral blood and secondary lymphoid organs of HD. Due to the altered composition of CD21<sup>low</sup> B cells in HD, including classical or atypical memory B-cell subsets and only very low proportions of na&#x000ef;ve-like CD21<sup>low</sup> B cells (<xref rid="B34" ref-type="bibr">34</xref>), the analysis in HD refers to &#x0201c;total&#x0201d; CD21<sup>low</sup> B cells, without differentiating CD27 and IgD expression. Also, in HD, increased SNA and reduced ECL staining corroborated hypersialylation of total CD21<sup>low</sup> B cells compared to CD21<sup>pos</sup> na&#x000ef;ve, IgM mem, and cs mem B cells (<xref rid="f3" ref-type="fig">
<bold>Figures&#x000a0;3A, B</bold>
</xref>), indicating that this glycosylation pattern is characteristic of the CD21<sup>low</sup> B-cell population and not limited to CVID. The degree of &#x003b1;2,6 surface sialylation was similar between the different blood-derived CD21<sup>pos</sup> B-cell subsets (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3A</bold>
</xref>) and, as previously published (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B35" ref-type="bibr">35</xref>), also between tonsillar B-cell populations (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figures S4A, B</bold>
</xref>). The level of terminal &#x003b2;1,4-linked galactose was significantly reduced in circulating cs mem B cells compared to na&#x000ef;ve and IgM mem B cells, yet still increased compared to CD21<sup>low</sup> B cells (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4B</bold>
</xref>). This difference was not seen for the B-cell populations from secondary lymphoid tissue (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S4C</bold>
</xref>).</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Cell surface glycome of HD B-cell subsets. Statistical analysis of the MFI for <bold>(A)</bold> SNA (<italic>n</italic> = 24), <bold>(B)</bold> ECL (<italic>n</italic> = 21), <bold>(C)</bold> AAL (<italic>n</italic> = 24), <bold>(D)</bold> LCA (<italic>n</italic> = 24), and <bold>(E)</bold>&#x000a0;anti-SLe<sup>X</sup> (<italic>n</italic> = 5) for HD B-cell subpopulations from peripheral blood. CD21<sup>low</sup> B cells were gated from total B cells, while other subsets were determined from non-CD21<sup>low</sup> B cells. Lectin/antibody-binding epitopes are illustrated. <italic>p</italic>-values as determined by one-way ANOVA with Tukey&#x02019;s multiple comparisons test <bold>(A&#x02013;C, E)</bold> and Friedman&#x02019;s test with Dunn&#x02019;s multiple comparisons test <bold>(D)</bold>. *p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.001; and ****p&#x000a0;&#x0003c; 0.0001.</p></caption><graphic xlink:href="fimmu-16-1512279-g003" position="float"/></fig><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Surface glycome of activated B cells. <bold>(A)</bold> Representative histogram showing the MFI of SNA in activated na&#x000ef;ve B cells from a HD after 48 h of <italic>in vitro</italic> stimulation, as indicated, and statistical analysis of the ratios of the MFI of stimulated to unstimulated (<italic>n</italic> = 11). <bold>(B&#x02013;D)</bold> Results after lectin staining with ECL (<italic>n</italic> = 5), AAL (<italic>n</italic> = 11), and LCA (<italic>n</italic> = 10) as described in <bold>(A)</bold>. Lectin-binding epitopes are illustrated. <italic>p</italic>-values as determined by Friedman&#x02019;s test with Dunn&#x02019;s multiple comparisons test <bold>(A, D)</bold> and one-way ANOVA with Tukey&#x02019;s multiple comparisons test <bold>(B, C)</bold>. *p &#x0003c; 0.05; and **p &#x0003c; 0.01.</p></caption><graphic xlink:href="fimmu-16-1512279-g004" position="float"/></fig><p>CD21<sup>low</sup> B cells from HD also revealed hyperfucosylation with increased expression of AAL, LCA, and anti-SLe<sup>X</sup> ligands (<xref rid="f3" ref-type="fig">
<bold>Figures&#x000a0;3C&#x02013;E</bold>
</xref>). Unlike the sialylation profile, fucosylation differed between the various CD21<sup>pos</sup> B-cell populations. We observed increasing levels of AAL ligands from the na&#x000ef;ve to the cs mem B-cell compartment, still not reaching the level seen in CD21<sup>low</sup> B cells (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3C</bold>
</xref>), while LCA binding was slightly increased on IgM mem B cells compared to na&#x000ef;ve and cs mem B cells (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3D</bold>
</xref>). Reduced expression of SLe<sup>X</sup> was observed in cs mem B cells (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3E</bold>
</xref>). Interestingly, in the secondary lymphoid tissue, the strongest AAL and LCA staining was detected in pre-germinal center cells and plasmablasts (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figures S4D, E</bold>
</xref>). Overall, HD CD21<sup>low</sup> B cells exhibited the same surface glycosylation pattern as na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients, with the highest levels of &#x003b1;2,6 sialic acids of all investigated B-cell subsets, reduced levels of terminal &#x003b2;1,4 galactose, and increased levels of &#x003b1;1,3, &#x003b1;1,4, and/or &#x003b1;1,6 fucose,&#x000a0;N-glycan core fucose, and SLe<sup>X</sup>. The direct comparison of total CD21<sup>low</sup> B cells in HD and CVID patient-derived na&#x000ef;ve-like CD21<sup>low</sup> B cells did not reveal significant differences (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S5</bold>
</xref>). Minor changes were observed for AAL, which tended to be higher in HD, or LCA, which was slightly lower in HD (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Figure S5</bold>
</xref>). These differences are most likely caused by the changes also observed in the CD21<sup>pos</sup> memory B-cell subsets compared to na&#x000ef;ve, and thus reflect the different composition of the underlying CD21<sup>low</sup> B-cell subsets in HD and CVID (<xref rid="f3" ref-type="fig">
<bold>Figures&#x000a0;3C, D</bold>
</xref>). Thus, the altered glycome of CD21<sup>low</sup> B cells is a general, yet unique and characteristic feature of this B-cell population.</p></sec><sec id="s3_3"><label>3.3</label><title>Cell surface glycome after <italic>in vitro</italic> activation of na&#x000ef;ve B cells</title><p>To investigate the impact of B-cell activation on the glycome, na&#x000ef;ve CD21<sup>pos</sup> B cells from HD were cultured for 48 h <italic>in vitro</italic> with CpG, anti-IgM, anti-IgM/IFN-&#x003b3;, or without stimulation. These conditions were chosen to distinguish the impact of BCR versus Toll-like receptor signals and, especially, the effect of the combined stimulation with anti-IgM/IFN-&#x003b3;, which has been shown to provide an important signal for increased expression of the transcription factor T-bet and the differentiation of CD21<sup>low</sup> B cells (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B36" ref-type="bibr">36</xref>).</p><p>All investigated stimuli increased the expression of SNA ligands on&#x000a0;the B-cell surface after 48 h compared to unstimulated cells, but anti-IgM/IFN-&#x003b3; stimulation induced significantly more &#x003b1;2,6-sialylated epitopes (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4A</bold>
</xref>). Unlike our observation of CD21<sup>low</sup> B cells <italic>ex vivo</italic>, B-cell activation also generally upregulated ECL ligands on the surface of activated cells, indicating a higher overall expression of terminal &#x003b2;1,4-linked galactose, irrespective of increased sialylation (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4B</bold>
</xref>). Analysis of fucose residues showed upregulation of AAL and LCA ligands upon each type of activation, reaching the highest levels after anti-IgM/IFN-&#x003b3; stimulation (<xref rid="f4" ref-type="fig">
<bold>Figures&#x000a0;4C, D</bold>
</xref>). In conclusion, all investigated conditions of B-cell activation led to the upregulation of SNA, ECL, AAL, and LCA ligands compared to unstimulated cells. A more potent role of anti-IgM/IFN-&#x003b3; stimulation was visible for the upregulation of SNA, AAL, and LCA ligands, indicating a significantly stronger &#x003b1;2,6 hypersialylation, &#x003b1;1,3, &#x003b1;1,4, and/or &#x003b1;1,6 hyperfucosylation, and N-glycan core fucosylation under this condition.</p></sec><sec id="s3_4"><label>3.4</label><title>Glycosylation-related genes in CD21<sup>low</sup> B cells and anti-IgM/IFN-&#x003b3;-stimulated B cells</title><p>The transcription of glycosylation-related genes is a key factor in the cellular regulation of expressed glycans (<xref rid="B37" ref-type="bibr">37</xref>). Given the prominent role of anti-IgM/IFN-&#x003b3; stimulation in the differentiation of the na&#x000ef;ve-like CD21<sup>low</sup> B-cell phenotype (<xref rid="B5" ref-type="bibr">5</xref>), we compared DEGs from anti-IgM/IFN-&#x003b3;-activated and unstimulated B cells from HD to DEGs of na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients and na&#x000ef;ve CD21<sup>pos</sup> B cells from HD <italic>ex vivo</italic>. A comparative analysis of selected genes involved in sialylation (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5</bold>
</xref>) and fucosylation (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6</bold>
</xref>) was performed. We focused on the expression of genes encoding for &#x003b1;2,6 sialyltransferases and &#x003b1;1,3, &#x003b1;1,4, or &#x003b1;1,6 fucosyltransferases, which are responsible for the generation of SNA, AAL, or LCA ligands, as well as genes contributing to the synthesis of the nucleotide sugars cytidine monophosphate (CMP)-sialic acid and guanosine diphosphate (GDP)-fucose as substrate for the respective glycosyltransferases.</p><fig position="float" id="f5"><label>Figure&#x000a0;5</label><caption><p>Sialylation-related genes in anti-IgM/IFN-&#x003b3;-activated B cells and na&#x000ef;ve-like CD21<sup>low</sup> B cells. <bold>(A)</bold> Heatmap of selected genes regulating sialylation, as determined by RNAseq of activated na&#x000ef;ve B cells after <italic>in vitro</italic> stimulation with anti-IgM/IFN-&#x003b3; compared to unstimulated cells. The expression of genes encoding for &#x003b1;2,6 sialyltransferases (i), sialidase (ii), enzymes involved in CMP-sialic acid <italic>de novo</italic> synthesis (iii), and sialic acid degradation (iv) is depicted. <bold>(B)</bold> Heatmap of sialylation-regulating genes identified by RNAseq of na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from HD <italic>ex vivo</italic>. <bold>(C)</bold> Schematic overview of gene expression involved in sialic acid metabolism after anti-IgM/IFN-&#x003b3; <italic>in vitro</italic> stimulation (yellow) and in na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic> (purple). Pathways include sialic acid salvage and CMP-Neu5Ac <italic>de novo</italic> synthesis as substrates for sialyltransferases (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Increased (&#x02191;), decreased (&#x02193;), or not clearly deviating (&#x02194;) gene expression is indicated. Large arrows indicate significant changes, while small ones indicate clear trends without reaching significance. The correct illustration of <italic>CMAS</italic> in the nucleus (<xref rid="B77" ref-type="bibr">77</xref>) was omitted for better visualisation. UDP, uridine diphosphate; GlcNAc, N-acetyl glucosamine; ManNAc, N-acetyl mannosamine; P, phosphate; Neu5Ac, N-acetyl neuraminic acid; CMP, cytidine monophosphate. <bold>(C)</bold> was created with <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>. *p &#x0003c; 0.05.</p></caption><graphic xlink:href="fimmu-16-1512279-g005" position="float"/></fig><fig position="float" id="f6"><label>Figure&#x000a0;6</label><caption><p>Fucosylation-related genes in anti-IgM/IFN-&#x003b3;-activated B cells and na&#x000ef;ve-like CD21<sup>low</sup> B cells. <bold>(A)</bold> Heatmap of selected genes of fucosylation in 48 h anti-IgM/IFN-&#x003b3;-stimulated na&#x000ef;ve B cells (IgM/IFN-&#x003b3;) compared to unstimulated cells. The expression of genes encoding for &#x003b1;1,3, &#x003b1;1,4, &#x003b1;1,6 and fucosyltransferases (i), fucosidases (ii), enzymes of the GDP-fucose salvage (iii), and <italic>de novo</italic> synthesis (iv) is depicted. <bold>(B)</bold> Heatmap of genes in na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients compared to na&#x000ef;ve CD21<sup>pos</sup> B cells from HD, as described in <bold>(A)</bold>. <bold>(C)</bold> Fucose salvage and GDP-fucose <italic>de novo</italic> synthesis as substrates for fucosyltransferases (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Increased (&#x02191;), decreased (&#x02193;), or not clearly deviating (&#x02194;) gene expression is indicated for anti-IgM/IFN-&#x003b3;-stimulated B cells (yellow) and na&#x000ef;ve-like CD21<sup>low</sup> B cells (purple). Large arrows indicate significance, while small ones a clear trend without reaching significance. The correct illustration of the extracellular localisation of <italic>FUCA2</italic> (<xref rid="B78" ref-type="bibr">78</xref>) was omitted for better visualization. GDP, guanosine diphosphate; Man, mannose; Fuc, fucose; ER, endoplasmic reticulum. <bold>(C)</bold> was created with <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>. *p &#x0003c; 0.05.</p></caption><graphic xlink:href="fimmu-16-1512279-g006" position="float"/></fig><p>Anti-IgM/IFN-&#x003b3; <italic>in vitro</italic>-stimulated B cells revealed diverse deviations in the expression of sialyltransferases that generate SNA epitopes by linking &#x003b1;2,6 sialic acid to galactose or N-acetyl galactosamine (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Only <italic>ST6GALNAC3</italic> tended to be upregulated in the activated B cells, while <italic>ST6GALNAC4</italic> and <italic>ST6GALNAC5</italic> were not differentially expressed, <italic>ST6GAL2</italic> tended&#x000a0;to be downregulated, and <italic>ST6GAL1</italic>, <italic>ST6GALNAC1</italic>, and <italic>ST6GALNAC6</italic> were significantly downregulated (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Ai</bold>
</xref>). Genes for sialidases (also known as neuraminidases) that remove sialic acid from sialic acid-containing glycans (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>), such as <italic>NEU1</italic> and <italic>NEU3</italic>, were not differentially expressed <italic>in vitro</italic> (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Aii</bold>
</xref>). Genes regulating the <italic>de novo</italic> pathway of CMP-Neu5Ac synthesis (<italic>NANS</italic>, <italic>NANP</italic>, and <italic>CMAS</italic> but not <italic>GNE</italic>) were significantly upregulated in anti-IgM/IFN-&#x003b3;-activated B cells (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Aiii</bold>
</xref>) (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). <italic>NPL</italic>, involved in the degradation of sialic acid, was significantly downregulated (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Aiv</bold>
</xref>) (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B44" ref-type="bibr">44</xref>).</p><p>The analysis of differentially expressed genes in na&#x000ef;ve-like CD21<sup>low</sup> B cells compared to na&#x000ef;ve HD B cells <italic>ex vivo</italic> revealed a significant upregulation of <italic>ST6GALNAC4</italic> and increased <italic>ST6GALNAC6</italic> expression, though not reaching significance. The expression of other &#x003b1;2,6 sialyltransferases, such as <italic>ST6GAL1</italic>, <italic>ST6GAL2</italic>, <italic>ST6GALNAC2</italic>, <italic>ST6GALNAC3</italic>, and <italic>ST6GALNAC5</italic> were unremarkable or tended to be downregulated (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Bi</bold>
</xref>). The sialidase <italic>NEU1</italic> tended to be upregulated in na&#x000ef;ve-like CD21<sup>low</sup> B cells, while others, such as <italic>NEU3</italic> and <italic>NEU4</italic>, were not differentially expressed (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Bii</bold>
</xref>). In contrast to the <italic>in vitro</italic>- activated B cells, <italic>NANS</italic> was the only significantly upregulated gene related to the <italic>de novo</italic> synthesis of CMP-sialic acid in na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic> (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>), while <italic>GNE</italic>, <italic>NANP</italic>, and <italic>CMAS</italic> were not differentially expressed (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Biii</bold>
</xref>). <italic>NPL</italic> was not differentially expressed <italic>ex vivo</italic> (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5Biv</bold>
</xref>).</p><p>Overall, the results suggest an increased <italic>de novo</italic> synthesis of CMP-sialic acid in anti-IgM/IFN-&#x003b3;-activated B cells and reduced sialic acid degradation potentially leading to increased substrate for sialyltransferases as the basis for &#x003b1;2,6 hypersialylation. In contrast, the &#x003b1;2,6 hypersialylation in na&#x000ef;ve-like CD21<sup>low</sup> B cells may reflect a multifactorial basis involving the <italic>de novo</italic> and salvage synthesis of CMP-sialic acid and upregulation of individual sialyltransferases (<xref rid="f5" ref-type="fig">
<bold>Figure&#x000a0;5C</bold>
</xref>).</p><p>None of the fucosyltransferases <italic>FUT3</italic> to <italic>FUT11</italic>, linking fucose &#x003b1;1,3, &#x003b1;1,4, and/or &#x003b1;1,6 to N-acetyl glucosamine (<xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>) and thus elicit AAL or LCA ligands, were differentially expressed in anti-IgM/IFN-&#x003b3;-stimulated B cells (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Ai</bold>
</xref>). In contrast, the <italic>FUCA1</italic> and <italic>FUCA2</italic> which remove fucose from fucosylated glycans, were significantly downregulated (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Aii</bold>
</xref>) (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). While activated B cells significantly upregulated <italic>FUOM</italic>, further genes of the fucose salvage pathway (<italic>FPGT, FCSK</italic>) were not differentially expressed (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Aiii</bold>
</xref>) (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). However, with <italic>GMDS</italic> and <italic>GFUS</italic>, all genes involved in the <italic>de novo</italic> synthesis of GDP-fucose were significantly upregulated <italic>in vitro</italic> (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Aiv</bold>
</xref>) (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>).</p><p>Our analysis of na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic> exhibited diverse expression of fucosyltransferases. <italic>FUT7</italic>, one of the &#x003b1;1,3 fucosyltransferases with the highest potency in creating the SLe<sup>X</sup> epitope (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>), and <italic>FUT8</italic>, the only known fucosyltransferase that can link fucose &#x003b1;1,6 to form N-glycan core fucose (<xref rid="B45" ref-type="bibr">45</xref>), were significantly upregulated (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Bi</bold>
</xref>). The significant upregulation of both fucosidases, <italic>FUCA1</italic> and <italic>FUCA2</italic>, in na&#x000ef;ve-like CD21<sup>low</sup> B cells (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Bii</bold>
</xref>) and the trend toward upregulation of <italic>FUOM</italic> suggests increased recycling of fucose in na&#x000ef;ve-like CD21<sup>low</sup> B cells, in the presence of regular expression of the other genes involved in the fucose salvage pathway, <italic>FPGT</italic> and <italic>FCSK</italic> (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Biii</bold>
</xref>). Genes of the <italic>de novo</italic> synthesis of GDP-fucose were not differentially expressed (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6Biv</bold>
</xref>).</p><p>As seen for sialylation, <italic>in vitro</italic> anti-IgM/IFN-&#x003b3;-activated B cells upregulate genes involved in the <italic>de novo</italic> synthesis of GDP-fucose, potentially resulting in increased substrate for fucosyltransferases as basis for hyperfucosylation. In contrast, the basis in na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic> seems to involve the upregulation of individual genes of fucosyltransferases and the fucose salvage pathway (<xref rid="f6" ref-type="fig">
<bold>Figure&#x000a0;6C</bold>
</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>During lymphocyte development, the cellular glycome undergoes continuous changes that are believed to be relevant for differentiation, cell&#x02013;cell interaction, and activation (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Although the understanding of the highly complex and dynamic glycome has advanced in recent years, the influence of specific glycan structures on individual cell types and differentiation phases, as well as their significance to immune system integrity and dysfunction, remains incomplete. Translation is further complicated by differences between humans and mice, despite conserved processes (<xref rid="B53" ref-type="bibr">53</xref>). In this study, we report the unique and characteristic glycosylation pattern of CD21<sup>low</sup> B cells.</p><p>Our data imply that na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients and CD21<sup>low</sup> B cells from healthy controls exhibit a comprehensively restructured cell surface glycome, characterised by uniquely high levels of &#x003b1;2,6-linked sialic acid and fucose. The common upregulation of &#x003b1;2,6 sialyltransferases (<italic>ST6GALNAC4</italic>, <italic>ST6GALNAC6)</italic>, along with <italic>NEU1</italic> and <italic>NANS</italic> in na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients, potentially increases substrate availability through enhanced sialic acid recycling and/or <italic>de novo</italic> synthesis of CMP-sialic acid (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>), suggesting a multifactorial basis for &#x003b1;2,6 hypersialylation in these cells. A multifactorial genesis likely underlies the hyperfucosylation observed in CD21<sup>low</sup> B cells, as the upregulation of <italic>FUT7</italic>, <italic>FUT8</italic>, <italic>FUCA1</italic>, <italic>FUCA2</italic>, and <italic>FUOM</italic> in na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients suggests the relevance of fucosyltransferases and their substrate availability, potentially stemming from increased recycling of fucose (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). While <italic>FUT8</italic> encodes a fucosyltransferase uniquely responsible in linking fucose &#x003b1;1,6, thereby forming N-glycan core fucose (<xref rid="B45" ref-type="bibr">45</xref>), the fucosyltransferase encoded by <italic>FUT7</italic> exhibits the highest potency in creating the &#x003b1;1,3 fucose-containing selectin ligand SLe<sup>X</sup> (<xref rid="B50" ref-type="bibr">50</xref>). The upregulation of these two fucosyltransferases in patients&#x02019; CD21<sup>low</sup> B cells may consequently contribute to the observed hyperfucosylation in these cells. Although the glycosidases <italic>NEU1</italic>, <italic>FUCA1</italic>, and <italic>FUCA2</italic>, which remove sialic acid and fucose from glycans (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>), are upregulated CD21<sup>low</sup> B cells, we observed increased &#x003b1;2,6 sialylation and &#x003b1;1,3, &#x003b1;1,4 and/or &#x003b1;1,6 fucosylation on CD21<sup>low</sup> B cells, suggesting a potentially ongoing reconstruction of the surface glycome. This hypothesis is strengthened by the increased activity of <italic>NEU1</italic>, which hydrolyses &#x003b1;2,3-linked sialic acid more rapidly than &#x003b1;2,6- or &#x003b1;2,8-linked sialic acid (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B54" ref-type="bibr">54</xref>), and by <italic>FUCA1</italic> and <italic>FUCA2</italic>, which preferentially hydrolyse fucose &#x003b1;1,2-linked to galactose than fucose &#x003b1;1,3-, &#x003b1;1,4-, and &#x003b1;1,6-linked to N-acetyl glucosamine (<xref rid="B41" ref-type="bibr">41</xref>).</p><p>Interestingly, the CD21<sup>low</sup> B-cell-related CD11c<sup>high</sup> B-cell population in SLE (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>) exhibits significant transcriptomic similarities in the expression of glycosylation-related genes, with marked upregulation of <italic>ST6GALNAC4</italic>, <italic>ST6GALNAC6</italic>, <italic>NEU1</italic>, <italic>NANS</italic>, <italic>FUT8</italic>, <italic>FUCA1</italic>, <italic>FUCA2</italic>, and <italic>FUOM</italic> (<xref rid="B57" ref-type="bibr">57</xref>). This further supports our hypothesis that hypersialylation and hyperfucosylation are general features of the CD21<sup>low</sup> B-cell population. In contrast, hypofucosylation has been reported in SLE-derived B cells without specific changes in the double-negative (CD27<sup>neg</sup>/IgD<sup>neg</sup>) atypical memory B-cell population (<xref rid="B16" ref-type="bibr">16</xref>). This finding clearly contrasts with the hyperfucosylation observed in na&#x000ef;ve-like CD21<sup>low</sup> B cells in our study. Whether this represents a true difference between na&#x000ef;ve-like CD21<sup>low</sup> B cells and double-negative (CD27<sup>neg</sup>/IgD<sup>neg</sup>) atypical memory B cells or a specific finding related to altered glycosylation in SLE requires further investigation.</p><p>Anti-IgM/IFN-&#x003b3; stimulation provides a nonredundant signal during the differentiation of CD21<sup>low</sup> B cells and induces the initial changes toward the CD21<sup>low</sup> B-cell phenotype (<xref rid="B5" ref-type="bibr">5</xref>). Consistent with our hypothesis of increased sialylation and fucosylation on CD21<sup>low</sup> B cells <italic>ex vivo</italic>, the combined anti-IgM/IFN-&#x003b3; stimulation was also the strongest inducer of &#x003b1;2,6 hypersialylation and &#x003b1;1,3, &#x003b1;1,4, and/or &#x003b1;1,6 hyperfucosylation in na&#x000ef;ve B cells among all the investigated stimuli. Significant upregulation of <italic>NANS</italic>, <italic>NANP</italic>, <italic>CMAS</italic>, <italic>GMDS</italic>, and <italic>GFUS</italic>&#x02014;the majority of genes involved in the <italic>de novo</italic> synthesis of CMP-sialic acid and GDP-fucose&#x02014;suggests a central role for these pathways <italic>in vitro</italic>, potentially providing increased substrate for the respective sialyl- and fucosyltransferases (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Thus, anti-IgM/IFN-&#x003b3;-driven B-cell activation most likely contributes to the altered glycome during the differentiation of CD21<sup>low</sup> B cells. Although presenting a similar surface glycosylation pattern, the mechanisms differ from those observed in na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic>, suggesting potential differences in glycosylation during the differentiation and maintenance of these cells. Still, we cannot exclude the effects of limiting culture conditions on the availability of respective substrates.</p><p>The understanding of these aberrations in the glycome of normal human B cells remains ambiguous. In mice, increased sialylation limits the antigen-presenting potential (<xref rid="B58" ref-type="bibr">58</xref>&#x02013;<xref rid="B60" ref-type="bibr">60</xref>). Sialic acids on antigen-presenting cells or the antigen itself can even induce B-cell tolerance, depending on interactions with Siglecs on the interacting cell, such as CD22 (Siglec 2) and/or Siglec G, the murine orthologue of Siglec 10 (<xref rid="B61" ref-type="bibr">61</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>). Thus, in the context of increased frequency of autoreactive BCR specificities in the CD21<sup>low</sup> B-cell population (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>), hypersialylation may reflect an attempt to regulate an exacerbated immune response in autoimmune settings. On the other hand, reduced levels of terminal &#x003b2;1,4-linked galactose on CD21<sup>low</sup> B cells may actively contribute to immune dysregulation by limiting the secretion of highly expressed galectin 1 from na&#x000ef;ve-like CD21<sup>low</sup> B cells, potentially favouring its intracellular retention (<xref rid="B67" ref-type="bibr">67</xref>). Since secreted galectin 1 counteracts Th1-driven immune responses (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>), reduced galectin 1 release by this B-cell subset may itself support a Th1 bias in its immediate neighbourhood, potentially contributing to a preferential type 1 immune response in different CD21<sup>low</sup> B-cell-associated disease conditions (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). Moreover, upregulated SLe<sup>X</sup> on CD21<sup>low</sup> B cells may support their accumulation in inflamed tissues, such as the synovia of inflamed joints in rheumatoid arthritis, where the expression of SLe<sup>X</sup>, recognising endothelial selectins, is increased (<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). Specific glycans mediate distinct functions. One of the most prominent examples is IgG: &#x003b1;2,6-linked sialylation of IgG conveys anti-inflammatory properties and reduces antibody-dependent cell-mediated cytotoxicity (ADCC) (<xref rid="B72" ref-type="bibr">72</xref>). Similarly, hyperfucosylation decreases ADCC (<xref rid="B73" ref-type="bibr">73</xref>). Notably, the secretion of IgG is low in antibody-deficient CVID patients. We cannot exclude the possibility that Ig substitution-mediated processes also play a role in the glycome changes observed in CD21<sup>low</sup> B cells from CVID patients, but given the strong similarities to the glycome of CD21<sup>low</sup> B cells in HD, this does not seem to be crucial. Unfortunately, the determination of the sialylation or fucosylation status of distinct surface proteins of CD21<sup>low</sup> B cells, such as CD45 or the BCR, known to be strongly influenced by glycosylation, was not feasible due to the limited number of primary B cells from immunodeficient patients.</p><p>It is noteworthy that increased sialylation, enhanced N-glycan core fucosylation, and elevated levels of SLe<sup>X</sup> on CD21<sup>low</sup> B cells are also seen in tumour cells, altering their cell interactions and modulating signal transduction (<xref rid="B74" ref-type="bibr">74</xref>). Tumour cells benefit from these aberrations, which foster their migration, promote their survival, and aid in immune evasion. These insights have opened new therapeutic strategies (<xref rid="B75" ref-type="bibr">75</xref>). The direct transfer of, for example, sialidase-conjugated antibodies mediating targeted desialylation of mammary carcinoma cells promoted the infiltration and activation of immune cells (<xref rid="B76" ref-type="bibr">76</xref>). A deeper understanding of the function and consequences of specific alterations in the glycome in human B cells is required before therapies targeting sialylation or fucosylation in CD21<sup>low</sup> B cells, or directly modulating glycan&#x02013;lectin interactions, can be applied as a therapeutic approach in CVID.</p><p>In summary, na&#x000ef;ve-like CD21<sup>low</sup> B cells from CVID patients and CD21<sup>low</sup> B cells from healthy controls exhibit a unique glycosylation pattern, expressing the highest levels of &#x003b1;2,6 sialic acid and high levels of &#x003b1;1,3-, &#x003b1;1,4-, and/or &#x003b1;1,6-linked fucose, including N-glycan core fucose and of SLeX. Unlike the more dynamic profile of fucosylation in different B-cell subpopulations, hypersialylation was unique for the CD21<sup>low</sup> B-cell phenotype. <italic>In vitro</italic> experiments indicate that these alterations are especially induced by the costimulation with anti-IgM/IFN-&#x003b3;, which represents a key mechanism in the differentiation of the T-bet-expressing CD21<sup>low</sup> B-cell population. RNAseq data depict a fundamental reorganisation of the cellular glycosylation machinery during and after the differentiation of this unique B-cell subset. Our findings add a new aspect to the functional consequences of a chronic type I immune response in complicated CVID patients, which may become relevant if glycome-targeting strategies are incorporated into the therapeutic arsenal against autoimmune diseases.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the patients for their willingness to participate in this study, and the physicians and study nurses of the CCI for patient care, patient information, and support. Samples for this project were obtained from the CCI Biobank, which is a partner biobank/hub of the University Medical Center Freiburg and the Medical Faculty&#x02019;s &#x0201c;Center for Biobanking - FREEZE&#x0201d;. We acknowledge the Lighthouse Core Facility unit for their excellent assistance with flow cytometry. Some figures were created with <ext-link xlink:href="http://Biorender.com" ext-link-type="uri">Biorender.com</ext-link>.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The datasets for anti-IgM/IFN-&#x003b3; <italic>in vitro</italic>-stimulated B cells compared to unstimulated cells, and for na&#x000ef;ve-like CD21<sup>low</sup> B cells <italic>ex vivo</italic> compared to HD CD21<sup>pos</sup> B cells, are available in the Gene Expression Omnibus data repository of the National Center for Biotechnology Information (<xref rid="B21" ref-type="bibr">21</xref>) under accession numbers GSE181739 and GSE148163, respectively.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by Ethik-Kommission der Albert-Ludwigs-Universit&#x000e4;t Freiburg, 251/13 and 254/19. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants or their legal guardians.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>PF: Data curation, Formal analysis, Investigation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. GA: Formal analysis, Investigation, Visualization, Writing &#x02013; original draft. AM: Resources, Writing &#x02013; original draft. SiG: Resources, Writing &#x02013; original draft. IH: Investigation, Writing &#x02013; original draft. SyG: Investigation, Writing &#x02013; original draft. JL: Formal analysis, Investigation, Writing &#x02013; original draft. VB: Supervision, Writing &#x02013; original draft. TJ: Resources, Writing &#x02013; original draft. MB: Formal analysis, Funding acquisition, Writing &#x02013; original draft. LN: Writing &#x02013; review &#x00026; editing. RV: Writing &#x02013; review &#x00026; editing, Resources. KW: Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. BK: Funding acquisition, Conceptualization, Methodology, Project administration, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1512279/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1512279/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="DataSheet1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chapel</surname><given-names>H</given-names></name><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Bjorkander</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>D</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Common variable immunodeficiency disorders: division into distinct clinical phenotypes</article-title>. <source>Blood</source>. (<year>2008</year>) <volume>112</volume>:<page-range>277&#x02013;86</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood-2007-11-124545</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wehr</surname><given-names>C</given-names></name><name><surname>Kivioja</surname><given-names>T</given-names></name><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Ferry</surname><given-names>B</given-names></name><name><surname>Witte</surname><given-names>T</given-names></name><name><surname>Eren</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>The EUROclass trial: defining subgroups in common variable immunodeficiency</article-title>. <source>Blood</source>. (<year>2008</year>) <volume>111</volume>:<fpage>77</fpage>&#x02013;<lpage>85</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood-2007-06-091744</pub-id>
<pub-id pub-id-type="pmid">17898316</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Seidl</surname><given-names>M</given-names></name><name><surname>van Schouwenburg</surname><given-names>P</given-names></name><name><surname>Rakhmanov</surname><given-names>M</given-names></name><name><surname>Bulashevska</surname><given-names>A</given-names></name><name><surname>Frede</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The TH1 phenotype of follicular helper T cells indicates an IFN-&#x003b3;-associated immune dysregulation in patients with CD21low common variable immunodeficiency</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2018</year>) <volume>141</volume>:<page-range>730&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2017.04.041</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rakhmanov</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>B</given-names></name><name><surname>Gutenberger</surname><given-names>S</given-names></name><name><surname>Foerster</surname><given-names>C</given-names></name><name><surname>Hoenig</surname><given-names>M</given-names></name><name><surname>Driessen</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2009</year>) <volume>106</volume>:<page-range>13451&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.0901984106</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keller</surname><given-names>B</given-names></name><name><surname>Strohmeier</surname><given-names>V</given-names></name><name><surname>Harder</surname><given-names>I</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>KJ</given-names></name><name><surname>Andrieux</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The expansion of human T-bethighCD21low B cells is T cell dependent</article-title>. <source>Sci Immunol</source>. (<year>2021</year>) <volume>6</volume>:<fpage>eabh0891</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/sciimmunol.abh0891</pub-id>
<pub-id pub-id-type="pmid">34623902</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wehr</surname><given-names>C</given-names></name><name><surname>Eibel</surname><given-names>H</given-names></name><name><surname>Masilamani</surname><given-names>M</given-names></name><name><surname>Illges</surname><given-names>H</given-names></name><name><surname>Schlesier</surname><given-names>M</given-names></name><name><surname>Peter</surname><given-names>H-H</given-names></name><etal/></person-group>. <article-title>A new CD21low B cell population in the peripheral blood of patients with SLE</article-title>. <source>Clin Immunol</source>. (<year>2004</year>) <volume>113</volume>:<page-range>161&#x02013;71</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.clim.2004.05.010</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Isnardi</surname><given-names>I</given-names></name><name><surname>Ng</surname><given-names>Y-S</given-names></name><name><surname>Menard</surname><given-names>L</given-names></name><name><surname>Meyers</surname><given-names>G</given-names></name><name><surname>Saadoun</surname><given-names>D</given-names></name><name><surname>Srdanovic</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones</article-title>. <source>Blood</source>. (<year>2010</year>) <volume>115</volume>:<page-range>5026&#x02013;36</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood-2009-09-243071</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saadoun</surname><given-names>D</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name><name><surname>Bannock</surname><given-names>J</given-names></name><name><surname>Vazquez</surname><given-names>T</given-names></name><name><surname>Massad</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Expansion of autoreactive unresponsive CD21-/low B cells in Sj&#x000f6;gren&#x02019;s syndrome-associated lymphoproliferation</article-title>. <source>Arthritis Rheumatol</source>. (<year>2013</year>) <volume>65</volume>:<page-range>1085&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/art.37828</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Malaspina</surname><given-names>A</given-names></name><name><surname>Ogwaro</surname><given-names>KM</given-names></name><name><surname>Donoghue</surname><given-names>ET</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><name><surname>Ehler</surname><given-names>LA</given-names></name><etal/></person-group>. <article-title>HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2001</year>) <volume>98</volume>:<page-range>10362&#x02013;7</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.181347898</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiss</surname><given-names>GE</given-names></name><name><surname>Crompton</surname><given-names>PD</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Walsh</surname><given-names>LA</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Traore</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>183</volume>:<page-range>2176&#x02013;82</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.0901297</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuzmina</surname><given-names>Z</given-names></name><name><surname>Krenn</surname><given-names>K</given-names></name><name><surname>Petkov</surname><given-names>V</given-names></name><name><surname>K&#x000f6;rm&#x000f6;czi</surname><given-names>U</given-names></name><name><surname>Weigl</surname><given-names>R</given-names></name><name><surname>Rottal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome</article-title>. <source>Blood</source>. (<year>2013</year>) <volume>121</volume>:<page-range>1886&#x02013;95</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1182/blood-2012-06-435008</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Diao</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name></person-group>. <article-title>T-bet-expressing B cells are positively associated with crohn&#x02019;s disease activity and support th1 inflammation</article-title>. <source>DNA Cell Biol</source>. (<year>2016</year>) <volume>35</volume>:<page-range>628&#x02013;35</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1089/dna.2016.3304</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Kooyk</surname><given-names>Y</given-names></name><name><surname>Rabinovich</surname><given-names>GA</given-names></name></person-group>. <article-title>Protein-glycan interactions in the control of innate and adaptive immune responses</article-title>. <source>Nat Immunol</source>. (<year>2008</year>) <volume>9</volume>:<fpage>593</fpage>&#x02013;<lpage>601</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni.f.203</pub-id>
<pub-id pub-id-type="pmid">18490910</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marth</surname><given-names>JD</given-names></name><name><surname>Grewal</surname><given-names>PK</given-names></name></person-group>. <article-title>Mammalian glycosylation in immunity</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>:<page-range>874&#x02013;87</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nri2417</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maverakis</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Shimoda</surname><given-names>M</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name><name><surname>Patel</surname><given-names>F</given-names></name><name><surname>Wilken</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review</article-title>. <source>J Autoimmun</source>. (<year>2015</year>) <volume>57</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaut.2014.12.002</pub-id>
<pub-id pub-id-type="pmid">25578468</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morel</surname><given-names>M</given-names></name><name><surname>Pochard</surname><given-names>P</given-names></name><name><surname>Echchih</surname><given-names>W</given-names></name><name><surname>Dueymes</surname><given-names>M</given-names></name><name><surname>Bagacean</surname><given-names>C</given-names></name><name><surname>Jousse-Joulin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>975963</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.975963</pub-id>
<pub-id pub-id-type="pmid">36091064</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reily</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>TJ</given-names></name><name><surname>Renfrow</surname><given-names>MB</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name></person-group>. <article-title>Glycosylation in health and disease</article-title>. <source>Nat Rev Nephrol</source>. (<year>2019</year>) <volume>15</volume>:<page-range>346&#x02013;66</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41581-019-0129-4</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name></person-group>. <article-title>Sialic acids and autoimmune disease</article-title>. <source>Immunol Rev</source>. (<year>2016</year>) <volume>269</volume>:<page-range>145&#x02013;61</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/imr.2016.269.issue-1</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varki</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>RD</given-names></name><name><surname>Aebi</surname><given-names>M</given-names></name><name><surname>Packer</surname><given-names>NH</given-names></name><name><surname>Seeberger</surname><given-names>PH</given-names></name><name><surname>Esko</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Symbol nomenclature for graphical representations of glycans</article-title>. <source>Glycobiology</source>. (<year>2015</year>) <volume>25</volume>:<page-range>1323&#x02013;4</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/cwv091</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Neelamegham</surname><given-names>S</given-names></name></person-group>. <article-title>DrawGlycan-SNFG: a robust tool to render glycans and glycopeptides with fragmentation information</article-title>. <source>Glycobiology</source>. (<year>2017</year>) <volume>27</volume>:<page-range>200&#x02013;5</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/cww115</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edgar</surname><given-names>R</given-names></name><name><surname>Domrachev</surname><given-names>M</given-names></name><name><surname>Lash</surname><given-names>AE</given-names></name></person-group>. <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>. (<year>2002</year>) <volume>30</volume>:<page-range>207&#x02013;10</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/nar/30.1.207</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Cummings</surname><given-names>RD</given-names></name><name><surname>Darvill</surname><given-names>AG</given-names></name><name><surname>Etzler</surname><given-names>ME</given-names></name><name><surname>Hahn</surname><given-names>MG</given-names></name></person-group>. <article-title>Glycan-recognizing probes as tools</article-title>. In: <person-group person-group-type="editor"><name><surname>Varki</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>RD</given-names></name><name><surname>Esko</surname><given-names>JD</given-names></name><name><surname>Stanley</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name><name><surname>Aebi</surname><given-names>M</given-names></name><etal/></person-group>, editors. <source>Essentials of Glycobiology</source>, <edition>3rd ed</edition>. <publisher-loc>Cold Spring Harbor, New York</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name> (<year>2017</year>). p. <fpage>48</fpage>.</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>N</given-names></name><name><surname>Goldstein</surname><given-names>IJ</given-names></name><name><surname>Broekaert</surname><given-names>WF</given-names></name><name><surname>Nsimba-Lubaki</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>B</given-names></name><name><surname>Peumans</surname><given-names>WJ</given-names></name></person-group>. <article-title>The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha2-6)Gal/GalNAc sequence</article-title>. <source>J Biol Chem</source>. (<year>1987</year>) <volume>262</volume>:<page-range>1596&#x02013;601</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0021-9258(19)75677-4</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iglesias</surname><given-names>JL</given-names></name><name><surname>Lis</surname><given-names>H</given-names></name><name><surname>Sharon</surname><given-names>N</given-names></name></person-group>. <article-title>Purification and properties of a D-galactose/N-acetyl-D-galactosamine-specific lectin from Erythrina cristagalli</article-title>. <source>Eur J Biochem</source>. (<year>1982</year>) <volume>123</volume>:<page-range>247&#x02013;52</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1432-1033.1982.tb19760.x</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochibe</surname><given-names>N</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name></person-group>. <article-title>Purification and properties of a novel fucose-specific hemagglutinin of Aleuria aurantia</article-title>. <source>Biochemistry</source>. (<year>1980</year>) <volume>19</volume>:<page-range>2841&#x02013;6</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1021/bi00554a004</pub-id>
</mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Hanes</surname><given-names>MS</given-names></name><name><surname>Byrd-Leotis</surname><given-names>LA</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>N</given-names></name><name><surname>Kardish</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Unique binding specificities of proteins toward isomeric asparagine-linked glycans</article-title>. <source>Cell Chem Biol</source>. (<year>2019</year>) <volume>26</volume>:<fpage>535</fpage>&#x02013;<lpage>547.e4</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.chembiol.2019.01.002</pub-id>
<pub-id pub-id-type="pmid">30745240</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kornfeld</surname><given-names>K</given-names></name><name><surname>Reitman</surname><given-names>ML</given-names></name><name><surname>Kornfeld</surname><given-names>R</given-names></name></person-group>. <article-title>The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant</article-title>. <source>J Biol Chem</source>. (<year>1981</year>) <volume>256</volume>:<page-range>6633&#x02013;40</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0021-9258(19)69037-X</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angiari</surname><given-names>S</given-names></name></person-group>. <article-title>Selectin-mediated leukocyte trafficking during the development of autoimmune disease</article-title>. <source>Autoimmun Rev</source>. (<year>2015</year>) <volume>14</volume>:<page-range>984&#x02013;95</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.autrev.2015.06.006</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barthel</surname><given-names>SR</given-names></name><name><surname>Gavino</surname><given-names>JD</given-names></name><name><surname>Descheny</surname><given-names>L</given-names></name><name><surname>Dimitroff</surname><given-names>CJ</given-names></name></person-group>. <article-title>Targeting selectins and selectin ligands in inflammation and cancer</article-title>. <source>Expert Opin Ther Targets</source>. (<year>2007</year>) <volume>11</volume>:<page-range>1473&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1517/14728222.11.11.1473</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group>. <article-title>The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins</article-title>. <source>Glycoconjugate J</source>. (<year>2020</year>) <volume>37</volume>:<page-range>277&#x02013;91</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s10719-020-09912-4</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelly</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>JM</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group>. <article-title>Modulating leukocyte recruitment in inflammation</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2007</year>) <volume>120</volume>:<fpage>3</fpage>&#x02013;<lpage>10</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jaci.2007.05.017</pub-id>
<pub-id pub-id-type="pmid">17559914</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McEver</surname><given-names>RP</given-names></name></person-group>. <article-title>Selectins: initiators of leucocyte adhesion and signalling at the vascular wall</article-title>. <source>Cardiovasc Res</source>. (<year>2015</year>) <volume>107</volume>:<page-range>331&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/cvr/cvv154</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sperandio</surname><given-names>M</given-names></name><name><surname>Gleissner</surname><given-names>CA</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group>. <article-title>Glycosylation in immune cell trafficking</article-title>. <source>Immunol Rev</source>. (<year>2009</year>) <volume>230</volume>:<fpage>97</fpage>&#x02013;<lpage>113</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00795.x</pub-id>
<pub-id pub-id-type="pmid">19594631</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freudenhammer</surname><given-names>M</given-names></name><name><surname>Voll</surname><given-names>RE</given-names></name><name><surname>Binder</surname><given-names>SC</given-names></name><name><surname>Keller</surname><given-names>B</given-names></name><name><surname>Warnatz</surname><given-names>K</given-names></name></person-group>. <article-title>Naive- and memory-like CD21low B cell subsets share core phenotypic and signaling characteristics in systemic autoimmune disorders</article-title>. <source>J Immunol</source>. (<year>2020</year>) <volume>205</volume>:<page-range>2016&#x02013;25</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.2000343</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macauley</surname><given-names>MS</given-names></name><name><surname>Kawasaki</surname><given-names>N</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S-H</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Arlian</surname><given-names>BM</given-names></name><etal/></person-group>. <article-title>Unmasking of CD22 co-receptor on germinal center B-cells occurs by alternative mechanisms in mouse and man</article-title>. <source>J Biol Chem</source>. (<year>2015</year>) <volume>290</volume>:<page-range>30066&#x02013;77</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M115.691337</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name></person-group>. <article-title>Stat1-dependent synergistic activation of T-bet for IgG2a production during early stage of B cell activation</article-title>. <source>J Immunol</source>. (<year>2005</year>) <volume>175</volume>:<page-range>7419&#x02013;24</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.175.11.7419</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ohtsubo</surname><given-names>K</given-names></name><name><surname>Marth</surname><given-names>JD</given-names></name></person-group>. <article-title>Glycosylation in cellular mechanisms of health and disease</article-title>. <source>Cell</source>. (<year>2006</year>) <volume>126</volume>:<page-range>855&#x02013;67</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.cell.2006.08.019</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harduin-Lepers</surname><given-names>A</given-names></name><name><surname>Vallejo-Ruiz</surname><given-names>V</given-names></name><name><surname>Krzewinski-Recchi</surname><given-names>M-A</given-names></name><name><surname>Samyn-Petit</surname><given-names>B</given-names></name><name><surname>Julien</surname><given-names>S</given-names></name><name><surname>Delannoy</surname><given-names>P</given-names></name></person-group>. <article-title>The human sialyltransferase family</article-title>. <source>Biochimie</source>. (<year>2001</year>) <volume>83</volume>:<page-range>727&#x02013;37</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0300-9084(01)01301-3</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takashima</surname><given-names>S</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Tsujimoto</surname><given-names>M</given-names></name></person-group>. <article-title>Characterization of the second type of human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Galbeta 1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human sialyltransferase genes</article-title>. <source>J Biol Chem</source>. (<year>2002</year>) <volume>277</volume>:<page-range>45719&#x02013;28</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M206808200</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyagi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name></person-group>. <article-title>Mammalian sialidases: physiological and pathological roles in cellular functions</article-title>. <source>Glycobiology</source>. (<year>2012</year>) <volume>22</volume>:<page-range>880&#x02013;96</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/cws057</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SW</given-names></name><name><surname>Alhadeff</surname><given-names>JA</given-names></name></person-group>. <article-title>Mammalian &#x003b1;-L-fucosidases</article-title>. <source>Comp Biochem Physiol</source>. (<year>1991</year>) <volume>99B</volume>:<page-range>479&#x02013;88</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/0305-0491(91)90327-A</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altheide</surname><given-names>TK</given-names></name><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Mikkelsen</surname><given-names>TS</given-names></name><name><surname>Diaz</surname><given-names>S</given-names></name><name><surname>Varki</surname><given-names>N</given-names></name><name><surname>Varki</surname><given-names>A</given-names></name></person-group>. <article-title>System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: Evidence for two modes of rapid evolution</article-title>. <source>J Biol Chem</source>. (<year>2006</year>) <volume>281</volume>:<page-range>25689&#x02013;702</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M604221200</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhide</surname><given-names>GP</given-names></name><name><surname>Colley</surname><given-names>KJ</given-names></name></person-group>. <article-title>Sialylation of N-glycans: mechanism, cellular compartmentalization and function</article-title>. <source>Histochem Cell Biol</source>. (<year>2017</year>) <volume>147</volume>:<page-range>149&#x02013;74</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s00418-016-1520-x</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wen</surname><given-names>X-Y</given-names></name><name><surname>Tarailo-Graovac</surname><given-names>M</given-names></name><name><surname>Brand-Arzamendi</surname><given-names>K</given-names></name><name><surname>Willems</surname><given-names>A</given-names></name><name><surname>Rakic</surname><given-names>B</given-names></name><name><surname>Huijben</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Sialic acid catabolism by N-acetylneuraminate pyruvate lyase is essential for muscle function</article-title>. <source>JCI Insight</source>. (<year>2018</year>) <volume>3</volume>:<fpage>e122373</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/jci.insight.122373</pub-id>
<pub-id pub-id-type="pmid">30568043</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>E</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The &#x003b1;1-6-fucosyltransferase gene and its biological significance</article-title>. <source>Biochim Biophys Acta Gen Subj</source>. (<year>1999</year>) <volume>1473</volume>:<fpage>9</fpage>&#x02013;<lpage>20</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0304-4165(99)00166-X</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollicone</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>SEH</given-names></name><name><surname>Bovin</surname><given-names>N</given-names></name><name><surname>Garcia-Rosasco</surname><given-names>M</given-names></name><name><surname>Candelier</surname><given-names>J-J</given-names></name><name><surname>Martinez-Duncker</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11)</article-title>. <source>J Biol Chem</source>. (<year>2009</year>) <volume>284</volume>:<page-range>4723&#x02013;38</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.M809312200</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vries</surname><given-names>T</given-names></name><name><surname>Knegtel</surname><given-names>RM</given-names></name><name><surname>Holmes</surname><given-names>EH</given-names></name><name><surname>Macher</surname><given-names>BA</given-names></name></person-group>. <article-title>Fucosyltransferases: structure/function studies</article-title>. <source>Glycobiology</source>. (<year>2001</year>) <volume>11</volume>:<page-range>119R&#x02013;28R</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/11.10.119R</pub-id>
</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Becker</surname><given-names>DJ</given-names></name><name><surname>Lowe</surname><given-names>JB</given-names></name></person-group>. <article-title>Fucose: biosynthesis and biological function in mammals</article-title>. <source>Glycobiology</source>. (<year>2003</year>) <volume>13</volume>:<fpage>41R</fpage>&#x02013;<lpage>53R</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/cwg054</pub-id>
</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>E</given-names></name><name><surname>Moriwaki</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name></person-group>. <article-title>Biological function of fucosylation in cancer biology</article-title>. <source>J Biochem</source>. (<year>2008</year>) <volume>143</volume>:<page-range>725&#x02013;9</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/jb/mvn011</pub-id>
</mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mondal</surname><given-names>N</given-names></name><name><surname>Dykstra</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Ashline</surname><given-names>DJ</given-names></name><name><surname>Reinhold</surname><given-names>VN</given-names></name><name><surname>Rossi</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Distinct human &#x003b1;(1,3)-fucosyltransferases drive Lewis-X/sialyl Lewis-X assembly in human cells</article-title>. <source>J Biol Chem</source>. (<year>2018</year>) <volume>293</volume>:<page-range>7300&#x02013;14</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1074/jbc.RA117.000775</pub-id>
</mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vicente</surname><given-names>MM</given-names></name><name><surname>Leite-Gomes</surname><given-names>E</given-names></name><name><surname>Pinho</surname><given-names>SS</given-names></name></person-group>. <article-title>Glycome dynamics in T and B cell development: basic immunological mechanisms and clinical applications</article-title>. <source>Trends Immunol</source>. (<year>2023</year>) <volume>44</volume>:<page-range>585&#x02013;97</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.it.2023.06.004</pub-id>
</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Giovannone</surname><given-names>N</given-names></name><name><surname>Antonopoulos</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Geddes Sweeney</surname><given-names>J</given-names></name><name><surname>Kudelka</surname><given-names>MR</given-names></name><name><surname>King</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Human B cell differentiation is characterized by progressive remodeling of O-linked glycans</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2857</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02857</pub-id>
<pub-id pub-id-type="pmid">30619255</pub-id>
</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>North</surname><given-names>SJ</given-names></name><name><surname>Chalabi</surname><given-names>S</given-names></name><name><surname>Sutton-Smith</surname><given-names>M</given-names></name><name><surname>Dell</surname><given-names>A</given-names></name><name><surname>Haslam</surname><given-names>SM</given-names></name></person-group>. <article-title>Mouse and human glycomes</article-title>. In: <person-group person-group-type="editor"><name><surname>Cummings</surname><given-names>RD</given-names></name><name><surname>Pierce</surname><given-names>JM</given-names></name></person-group>, editors. <source>Handbook of Glycomics</source>, <edition>1st</edition>. <publisher-name>Academic Press/Elsevier</publisher-name>, <publisher-loc>Amsterdam, Boston</publisher-loc> (<year>2009</year>). p. <fpage>263</fpage>&#x02013;<lpage>327</lpage>.</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miyagi</surname><given-names>T</given-names></name><name><surname>Tsuiki</surname><given-names>S</given-names></name></person-group>. <article-title>Rat-liver lysosomal sialidase. Solubilization, substrate specificity and comparison with the cytosolic sialidase</article-title>. <source>Eur J Biochem</source>. (<year>1984</year>) <volume>141</volume>:<fpage>75</fpage>&#x02013;<lpage>81</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1432-1033.1984.tb08159.x</pub-id>
<pub-id pub-id-type="pmid">6723666</pub-id>
</mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gjertsson</surname><given-names>I</given-names></name><name><surname>McGrath</surname><given-names>S</given-names></name><name><surname>Grimstad</surname><given-names>K</given-names></name><name><surname>Jonsson</surname><given-names>CA</given-names></name><name><surname>Camponeschi</surname><given-names>A</given-names></name><name><surname>Thorarinsdottir</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>A close-up on the expanding landscape of CD21-/low B cells in humans</article-title>. <source>Clin Exp Immunol</source>. (<year>2022</year>) <volume>210</volume>:<page-range>217&#x02013;29</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/cei/uxac103</pub-id>
</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rincon-Arevalo</surname><given-names>H</given-names></name><name><surname>Wiedemann</surname><given-names>A</given-names></name><name><surname>Stefanski</surname><given-names>A-L</given-names></name><name><surname>Lettau</surname><given-names>M</given-names></name><name><surname>Szelinski</surname><given-names>F</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Deep phenotyping of CD11c+ B cells in systemic autoimmunity and controls</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>635615</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.635615</pub-id>
<pub-id pub-id-type="pmid">33777025</pub-id>
</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maul</surname><given-names>RW</given-names></name><name><surname>Catalina</surname><given-names>MD</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Bachali</surname><given-names>P</given-names></name><name><surname>Grammer</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Transcriptome and igH repertoire analyses show that CD11chi B cells are a distinct population with similarity to B cells arising in autoimmunity and infection</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>649458</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.649458</pub-id>
<pub-id pub-id-type="pmid">33815408</pub-id>
</mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bagria&#x000e7;ik</surname><given-names>E&#x000dc;</given-names></name><name><surname>Miller</surname><given-names>KS</given-names></name></person-group>. <article-title>Cell surface sialic acid and the regulation of immune cell interactions: the neuraminidase effect reconsidered</article-title>. <source>Glycobiology</source>. (<year>1999</year>) <volume>9</volume>:<page-range>267&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/glycob/9.3.267</pub-id>
</mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frohman</surname><given-names>M</given-names></name><name><surname>Cowing</surname><given-names>C</given-names></name></person-group>. <article-title>Presentation of antigen by B cells: functional dependence on radiation dose, interleukins, cellular activation, and differential glycosylation</article-title>. <source>J Immunol</source>. (<year>1985</year>) <volume>134</volume>:<page-range>2269&#x02013;75</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.134.4.2269</pub-id>
</mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>Z</given-names></name><name><surname>Marques</surname><given-names>G</given-names></name><name><surname>Ferro</surname><given-names>T</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>M</given-names></name><name><surname>Monteiro</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses</article-title>. <source>Oncotarget</source>. (<year>2016</year>) <volume>7</volume>:<page-range>41053&#x02013;66</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.18632/oncotarget.v7i27</pub-id>
</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duong</surname><given-names>BH</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Completo</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Vela</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance <italic>in vivo</italic>
</article-title>. <source>J Exp Med</source>. (<year>2010</year>) <volume>207</volume>:<page-range>173&#x02013;87</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1084/jem.20091873</pub-id>
</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macauley</surname><given-names>MS</given-names></name><name><surname>Paulson</surname><given-names>JC</given-names></name></person-group>. <article-title>Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells</article-title>. <source>J Immunol</source>. (<year>2014</year>) <volume>193</volume>:<page-range>4312&#x02013;21</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1401723</pub-id>
</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macauley</surname><given-names>MS</given-names></name><name><surname>Pfrengle</surname><given-names>F</given-names></name><name><surname>Rademacher</surname><given-names>C</given-names></name><name><surname>Nycholat</surname><given-names>CM</given-names></name><name><surname>Gale</surname><given-names>AJ</given-names></name><name><surname>von Drygalski</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis</article-title>. <source>J Clin Invest</source>. (<year>2013</year>) <volume>123</volume>:<page-range>3074&#x02013;83</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1172/JCI69187</pub-id>
</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pfrengle</surname><given-names>F</given-names></name><name><surname>Macauley</surname><given-names>MS</given-names></name><name><surname>Kawasaki</surname><given-names>N</given-names></name><name><surname>Paulson</surname><given-names>JC</given-names></name></person-group>. <article-title>Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>191</volume>:<page-range>1724&#x02013;31</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.4049/jimmunol.1300921</pub-id>
</mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tipton</surname><given-names>CM</given-names></name><name><surname>Fucile</surname><given-names>CF</given-names></name><name><surname>Darce</surname><given-names>J</given-names></name><name><surname>Chida</surname><given-names>A</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Gregoretti</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus</article-title>. <source>Nat Immunol</source>. (<year>2015</year>) <volume>16</volume>:<page-range>755&#x02013;65</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni.3175</pub-id>
</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Karnell</surname><given-names>JL</given-names></name><name><surname>Naiman</surname><given-names>B</given-names></name><name><surname>Gross</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>1758</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-018-03750-7</pub-id>
<pub-id pub-id-type="pmid">29717110</pub-id>
</mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seelenmeyer</surname><given-names>C</given-names></name><name><surname>Wegehingel</surname><given-names>S</given-names></name><name><surname>Tews</surname><given-names>I</given-names></name><name><surname>K&#x000fc;nzler</surname><given-names>M</given-names></name><name><surname>Aebi</surname><given-names>M</given-names></name><name><surname>Nickel</surname><given-names>W</given-names></name></person-group>. <article-title>Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1</article-title>. <source>J Cell Biol</source>. (<year>2005</year>) <volume>171</volume>:<page-range>373&#x02013;81</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1083/jcb.200506026</pub-id>
</mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toscano</surname><given-names>MA</given-names></name><name><surname>Bianco</surname><given-names>GA</given-names></name><name><surname>Ilarregui</surname><given-names>JM</given-names></name><name><surname>Croci</surname><given-names>DO</given-names></name><name><surname>Correale</surname><given-names>J</given-names></name><name><surname>Hernandez</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death</article-title>. <source>Nat Immunol</source>. (<year>2007</year>) <volume>8</volume>:<page-range>825&#x02013;34</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/ni1482</pub-id>
</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Motran</surname><given-names>CC</given-names></name><name><surname>Molinder</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>SD</given-names></name><name><surname>Poirier</surname><given-names>F</given-names></name><name><surname>Miceli</surname><given-names>MC</given-names></name></person-group>. <article-title>Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function</article-title>. <source>Eur J Immunol</source>. (<year>2008</year>) <volume>38</volume>:<page-range>3015&#x02013;27</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1002/eji.200838295</pub-id>
</mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Jackson</surname><given-names>KJL</given-names></name><name><surname>Ogishi</surname><given-names>M</given-names></name><name><surname>Benhsaien</surname><given-names>I</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Human T-bet governs the generation of a distinct subset of CD11chighCD21low B cells</article-title>. <source>Sci Immunol</source>. (<year>2022</year>) <volume>7</volume>:<fpage>eabq3277</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1126/sciimmunol.abq3277</pub-id>
<pub-id pub-id-type="pmid">35867801</pub-id>
</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Munagala</surname><given-names>I</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Blankenship</surname><given-names>D</given-names></name><name><surname>Maffucci</surname><given-names>P</given-names></name><name><surname>Chaussabel</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Interferon signature in the blood in inflammatory common variable immune deficiency</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e74893</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1371/journal.pone.0074893</pub-id>
<pub-id pub-id-type="pmid">24069364</pub-id>
</mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name></person-group>. <article-title>Biological function of sialic acid and sialylation in human health and disease</article-title>. <source>Cell Death Discovery</source>. (<year>2024</year>) <volume>10</volume>:<fpage>415</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41420-024-02180-3</pub-id>
<pub-id pub-id-type="pmid">39349440</pub-id>
</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group>. <article-title>Core fucosylation regulates the function of pre-BCR, BCR and igG in humoral immunity</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>844427</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.844427</pub-id>
<pub-id pub-id-type="pmid">35401499</pub-id>
</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinho</surname><given-names>SS</given-names></name><name><surname>Reis</surname><given-names>CA</given-names></name></person-group>. <article-title>Glycosylation in cancer: mechanisms and clinical implications</article-title>. <source>Nat Rev Cancer</source>. (<year>2015</year>) <volume>15</volume>:<page-range>540&#x02013;55</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/nrc3982</pub-id>
</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Ju</surname><given-names>T</given-names></name></person-group>. <article-title>Aberrant glycosylation as immune therapeutic targets for solid tumors</article-title>. <source>Cancers (Basel)</source>. (<year>2023</year>) <volume>15</volume>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/cancers15143536</pub-id>
</mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gray</surname><given-names>MA</given-names></name><name><surname>Stanczak</surname><given-names>MA</given-names></name><name><surname>Mantuano</surname><given-names>NR</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Pijnenborg</surname><given-names>JFA</given-names></name><name><surname>Malaker</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Targeted glycan degradation potentiates the anticancer immune response <italic>in vivo</italic>
</article-title>. <source>Nat Chem Biol</source>. (<year>2020</year>) <volume>16</volume>:<page-range>1376&#x02013;84</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41589-020-0622-x</pub-id>
</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kean</surname><given-names>EL</given-names></name><name><surname>M&#x000fc;nster-K&#x000fc;hnel</surname><given-names>AK</given-names></name><name><surname>Gerardy-Schahn</surname><given-names>R</given-names></name></person-group>. <article-title>CMP-sialic acid synthetase of the nucleus</article-title>. <source>Biochim Biophys Acta Gen Subj</source>. (<year>2004</year>) <volume>1673</volume>:<fpage>56</fpage>&#x02013;<lpage>65</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.bbagen.2004.04.006</pub-id>
</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name></person-group>. <article-title>Dual role of fucosidase in cancers and its clinical potential</article-title>. <source>J Cancer</source>. (<year>2022</year>) <volume>13</volume>:<page-range>3121&#x02013;32</page-range>. doi:&#x000a0;<pub-id pub-id-type="doi">10.7150/jca.75840</pub-id>
</mixed-citation></ref></ref-list><glossary><title>Glossary</title><def-list><def-item><term>AAL</term><def><p>
<italic>Aleuria aurantia</italic> lectin</p></def></def-item><def-item><term>ADCC</term><def><p>antibody-dependent cell-mediated cytotoxicity</p></def></def-item><def-item><term>AIC</term><def><p>autoimmune cytopenia</p></def></def-item><def-item><term>AIO</term><def><p>autoimmune organ manifestation</p></def></def-item><def-item><term>APC</term><def><p>allophycocyanin</p></def></def-item><def-item><term>BCR</term><def><p>B-cell receptor</p></def></def-item><def-item><term>CMAS</term><def><p>cytidine monophosphate N-acetylneuraminic acid synthetase</p></def></def-item><def-item><term>Cs mem</term><def><p>class-switched memory</p></def></def-item><def-item><term>CMP</term><def><p>cytidine 5&#x02032;-monophosphate</p></def></def-item><def-item><term>CVID</term><def><p>common variable immunodeficiency</p></def></def-item><def-item><term>DEGs</term><def><p>differentially expressed genes</p></def></def-item><def-item><term>ECL</term><def><p>
<italic>Erythrina cristagalli</italic> lectin</p></def></def-item><def-item><term>FCSK</term><def><p>fucose kinase</p></def></def-item><def-item><term>FPGT</term><def><p>fucose-1-phosphate guanylyltransferase</p></def></def-item><def-item><term>FUCA1</term><def><p>alpha-L-fucosidase 1</p></def></def-item><def-item><term>FUCA2</term><def><p>alpha-L-fucosidase 2</p></def></def-item><def-item><term>FUT3-11</term><def><p>fucosyltransferase 3-11</p></def></def-item><def-item><term>FUOM</term><def><p>fucose mutarotase</p></def></def-item><def-item><term>GDP</term><def><p>guanosine 5&#x02032;-diphosphate</p></def></def-item><def-item><term>GFUS</term><def><p>GDP-L-fucose synthase</p></def></def-item><def-item><term>GLILD</term><def><p>granulomatous lymphocytic interstitial lung disease</p></def></def-item><def-item><term>GMDS</term><def><p>GDP-mannose 4,6-dehydratase</p></def></def-item><def-item><term>GNE</term><def><p>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</p></def></def-item><def-item><term>HD</term><def><p>healthy donor</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p>interferon &#x003b3;</p></def></def-item><def-item><term>IgM mem</term><def><p>IgM memory</p></def></def-item><def-item><term>ILD</term><def><p>interstitial lung disease</p></def></def-item><def-item><term>IMDM</term><def><p>Iscove&#x02019;s modified Dulbecco&#x02019;s medium</p></def></def-item><def-item><term>LCA</term><def><p>
<italic>Lens culinaris</italic> agglutinin</p></def></def-item><def-item><term>LP</term><def><p>lymphoproliferation</p></def></def-item><def-item><term>MFI</term><def><p>mean fluorescence intensity</p></def></def-item><def-item><term>NANP</term><def><p>N-acetylneuraminic acid phosphatase</p></def></def-item><def-item><term>NANS</term><def><p>N-acetylneuraminate synthase</p></def></def-item><def-item><term>NEU1</term><def><p>neuraminidase 1</p></def></def-item><def-item><term>NEU3</term><def><p>neuraminidase 3</p></def></def-item><def-item><term>NEU4</term><def><p>neuraminidase 4</p></def></def-item><def-item><term>NPL</term><def><p>N-acetylneuraminate pyruvate lyase</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>RA</term><def><p>rheumatoid arthritis</p></def></def-item><def-item><term>RNAseq</term><def><p>RNA-sequencing</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SLe<sup>X</sup>
</term><def><p>sialyl-Lewis X</p></def></def-item><def-item><term>SNA</term><def><p>
<italic>Sambucus nigra</italic> agglutinin</p></def></def-item><def-item><term>SLE</term><def><p>systemic lupus erythematosus</p></def></def-item><def-item><term>ST6GAL1-2</term><def><p>ST6 Beta-galactoside alpha-2,6-sialyltransferase 1-2</p></def></def-item><def-item><term>ST6GALNAC1-6</term><def><p>ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1-6</p></def></def-item><def-item><term>T-bet</term><def><p>T-box expressed in T cells.</p></def></def-item></def-list></glossary></back></article>